PumasAI releases Pumas 2.9 with expanded modeling and simulation tools

PumasAI launched Pumas 2.9 on November 6, 2026, adding new estimation methods, faster computation, and more reproducible workflows for clinical pharmacology and pharmacometrics. The update is aimed at helping drug developers handle more complex models with greater confidence and efficiency.

Why it matters: - Pumas 2.9 is built for clinical pharmacology and pharmacometrics teams that need faster, more stable modeling across complex drug development workflows. - The release is designed to improve estimation, reproducibility and computational performance, which can shorten analysis cycles and reduce workflow friction. - PumasAI says the update helps pharmaceutical and biotechnology organizations analyze complex data with greater confidence and efficiency.

What happened: - PumasAI announced Pumas 2.9 on November 6, 2026. - The software update adds expanded modeling capabilities, improved computational performance and greater reproducibility. - PumasAI said the release extends the AI capabilities introduced in Pumas 2.8 through PumasAide. - Pumas 2.9 is available through the validated JuliaHub cloud environment and for desktop deployment. - Students, professors and academic researchers can receive complimentary access for non-commercial education and research. - More information is available in the company's product page.

The details: - Expanded advanced estimation includes continued enhancements to the experimental Monte Carlo Expectation Maximization and Variational Expectation Maximization methods. - Those estimation updates are intended to improve stability, reliability and support for more complex nonlinear mixed-effects models. - Improved computational performance includes new multithreading capabilities, distributed computing enhancements and intelligent load balancing. - Those changes accelerate simulations, diagnostics, inference and estimation across demanding modeling workflows. - Greater reproducibility includes improvements to deterministic calculations and reproducible inference across parallel computing environments. - The reproducibility updates are meant to improve consistency and confidence in scientific results. - Expanded modeling flexibility adds support for ordered parameter domains, enhanced covariate selection, richer prediction outputs, expanded error model capabilities and additional inference tools. - Enhanced user experience includes improved diagnostics, clearer documentation, expanded error reporting and workflow refinements. - Pumas supports nonlinear mixed-effects modeling, optimal design, Bayesian analyses, SAEM, Monte Carlo Expectation Maximization, Variational Expectation Maximization, clinical trial simulation, machine learning, noncompartmental analysis and bioequivalence studies in one software environment. - PumasAI said the unified platform helps teams avoid fragmented workflows across multiple software platforms. - The company said that setup can reduce operational complexity and accelerate analyses across the drug development lifecycle.

Between the lines: - The release shows PumasAI is pushing deeper into the high-end scientific computing needs of drug developers, not just adding surface-level features. - Better reproducibility and distributed computing matter because pharmacometric work often runs across large datasets and parallel environments where small inconsistencies can undermine confidence in results. - The emphasis on a unified platform suggests PumasAI is trying to win users who want fewer handoffs between modeling, simulation and analysis tools.

What's next: - PumasAI said it remains focused on giving scientists more advanced computational tools that are faster, more reliable and easier to use. - The company said future work will continue to support researchers as clinical pharmacology evolves and as teams look for ways to accelerate new therapy development. - PumasAI also offers consulting in clinical pharmacology, model-informed drug development, pharmacometrics and related areas.

The bottom line: - Pumas 2.9 is a technical upgrade aimed at making complex pharmacometric modeling faster, more reproducible and easier to run inside one platform.